JP Morgan 2022 roundup – Biogen in focus
Much of this week’s business development might be done and dusted, but for Biogen things are just warming up.
JP Morgan 2022 – day one sees healthy deal flow from biopharma
But transactions are small, and mostly involve licensing rather than takeouts, with cancer and gene editing featuring heavily.
Big beasts drive biopharma valuations higher in 2021
A handful of huge success stories mask disappointing performances elsewhere, with small caps and Asian pharma firms feeling the pain.
Bavarian Nordic goes it alone, for now
Phase 3 in RSV will begin without a partner, while decent Covid-19 booster data pave the way for pivotal development.
US backs another Covid-19 booster
But a potentially more interesting advisory committee, for Merck and Ridgeback’s molnupiravir, awaits.
Triple meeting – low-profile assets boost Merus and Bicycle
Merus regains some lost pride while Bicycle rides to even greater heights.
Biopharma’s stock market winners and losers so far this year
Moderna is the standout gainer, but the stragglers are becoming more apparent as the pandemic tide retreats.
